Stay updated on Nivolumab in Advanced Cutaneous Squamous Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in Advanced Cutaneous Squamous Cell Carcinoma Clinical Trial page.

Latest updates to the Nivolumab in Advanced Cutaneous Squamous Cell Carcinoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check8 days agoChange DetectedThe record for a phase II study evaluating nivolumab in patients with advanced cutaneous squamous cell carcinoma is now available, including its treatment plan, eligibility criteria, study locations, and outcome measures.SummaryDifference40%

- Check16 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check23 days agoChange DetectedA sitewide notice was added announcing NIH’s transition from the term “Artificial Intelligence” to “Super Intelligence” and linking to updates and FAQs.SummaryDifference1%

- Check30 days agoChange DetectedThe footer revision identifier changes from v3.7.1 to v3.7.2, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check37 days agoChange DetectedThe ClinicalTrials.gov footer revision label changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check58 days agoChange DetectedThe page now displays a 403 Forbidden error screen, replacing the usual study record content. Visible elements include the 403 header and standard footer, signaling restricted access and preventing interaction with the page.SummaryDifference17%

Stay in the know with updates to Nivolumab in Advanced Cutaneous Squamous Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in Advanced Cutaneous Squamous Cell Carcinoma Clinical Trial page.